Related Experiment Video
Updated: Sep 25, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy
1Department of Gynecologic Oncology & Department of Clinical Trial & Research, Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad Avenue, 8D, Mathur Sen Garden Lane, Kolkata, 700094, India. ck.bose@nscri.in.
Abstract:
In recent years, approval of some immunotherapy based on markers such as dMMR, tumour mutational burden and other few such markers is not received well as shown in post-approval data published. The context of such approvals and controversies is discussed briefly.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cell-mediated Immune Responses
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

